EMCM B.V., a Dutch subsidiary and member of the aap Implantate AG Group, a medical technology company listed in the Frankfurt Stock Exchange’s Prime Standard segment, today signed with a distribution partner an open-ended exclusive license agreement on the utilization of the intellectual property of a product in the field of medical aesthetics with a total value of EUR 3.0 million. By the terms of the agreement, aap will continue to manufacture and supply the product under contract.

This contract relate to a line of business that is no longer core business area for aap and clearly testify to the implementation of the Group’s strategic realignment and its focus on Ortho/Trauma/Spine business.

Due to the effects of the above-mentioned contract at the sales and earnings level, the aap Management Board sees its forecast of profitable growth this financial year confirmed. It specifically anticipates an EBITDA of between EUR 5.0 million and EUR 7.0 million.

Together with another recent contract with a global partner to supply bone cement for use in spinal surgery and traumatology, also the groundwork for business development in 2010 is laid. Shipping of the bone cement will begin in the current financial year, and the signing of this agreement confirms once again aap’s leading position in this field.